This week I look back at a list of undervalued and overvalued stocks I picked in 2021 to see how they have performed since. Read More

An increasing body of evidence indicates that marijuana can actually help curb opioid addiction. Here's what it means for investors. Read More

Now that the major opioid lawsuit has been settled, we wouldn’t be surprised to see JNJ follow Merck's lead and break up into smaller pieces. Read More

This week, we show the most undervalued and overvalued Dow companies, according to consensus Wall Street targets. Read More

The November 3 elections witnessed the passage by wide margins of ballot measures to curb prohibitions on psychedelics. A major industry is being born. Read More

By betting on this "Big Pharma" buyout of a small-cap biotech, one group of investors stands to earn more than 10 times their money. Read More

The trade war is spooking investors. Volatility is off the charts. Market anxiety got you down? Here’s a time-tested method to pull yourself up. Read More

Merck has been a money-making machine for decades, but it faces growing competition and patent expirations. Will this drug giant prevail? Read More

Pfizer is a growth-and-income stock found in many retirement portfolios. But is the competition from biotech "disruptors" getting too hot for this Big Pharma stalwart? Read More

Health services giant Johnson & Johnson has been a reliable growth-and-income stock for years, but can it overcome the scandal about its allegedly carcinogenic talcum powder? Read More